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Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, is an autosomal recessive genetic
disorder caused by different SMPD1 mutations. Historically, ASMD has been classified as Niemann-Pick disease (NPD)
types A (NPD A) and B (NPD B). NPD A is associated with a uniformly devastating disease course, with rapidly
progressing psychomotor degeneration, leading to death typically by the age of 3 years, most often from
respiratory failure. In contrast, the clinical phenotype and life expectancy of patients with NPD B may vary widely.
Almost all patients have hepatosplenomegaly and an atherogenic lipid profile, and most patients have interstitial
lung disease with progressive impairment of pulmonary function and hematologic abnormalities including
cytopenias. Other common clinical manifestations include liver dysfunction, heart disease, skeletal abnormalities and
growth delays. Some patients with ASMD who survive beyond early childhood have intermediate phenotypes
(variant NPD B) characterized by combinations of non-neurologic and mild to severe neurologic symptoms. The
physical and psychosocial burden of illness in patients with NPD B is substantial. Common symptoms include
shortness of breath, joint or limb pain, abdominal pain, bleeding and bruising. The disease often leads to chronic
fatigue, limited physical or social activity and difficulties in performing daily activities or work. Many patients die
before or in early adulthood, often from pneumonia/respiratory failure or liver failure. Available treatments are
limited to symptom management and supportive care. An enzyme replacement therapy currently in clinical
development is expected to be the first treatment addressing the underlying pathology of the disease. Early
diagnosis and appropriate management are essential for reducing the risk of complications. While knowledge
about ASMD is evolving, more evidence about ASMD and the natural history across the disease spectrum is
needed, to improve disease recognition, timely diagnosis and appropriate disease management.
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Acid sphingomyelinase (ASM) deficiency (ASMD), a rare
lysosomal storage disease, is an autosomal recessive gen-
etic disorder caused by mutations in the SMPD1 gene
[1, 2]. Historically, ASMD has been classified as
Niemann-Pick disease type A (NPD A) and Niemann-
Pick disease type B (NPD B). NPD A patients have a
relatively uniform natural history characterized by severe
progressive neurodegeneration in the first year and death* Correspondence: Margaret.McGovern@stonybrook.edu
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disease course and is associated with a broad spectrum
of disease severity and manifestations [5]. The term
‘intermediate form’ or ‘variant NPD B’ has also been
used to characterize the phenotypes in patients who sur-
vive early childhood, and have combinations of non-
neurological and also mild-to-severe neurological mani-
festations [4, 6–8]. Importantly, ASMD represents a dis-
ease with a continuum of severity that may not be well
defined by the historic NPD A and B classification. In
the past, ASMD has also been erroneously grouped with
NPD type C (NPD C), a lysosomal storage disorder that
is genetically distinct from ASMD, but shares somele is distributed under the terms of the Creative Commons Attribution 4.0
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[9–11]. Currently, the management of ASMD is limited
to symptomatic treatment and supportive care [9]. More
evidence is required about ASMD and its natural history
across the disease spectrum, in order to raise awareness
of the disease among healthcare professionals and to in-
form clinical decision-making. Accordingly, the objective
of this review was to collate and synthesize information
available from the published literature on the clinical
manifestations and natural history of ASMD, and burden
of illness, to help facilitate disease awareness and to sup-




ASMD, also known as NPD types A (NPD A) and B
(NPD B), is a rare autosomal recessive lysosomal storage
disorder caused by mutations1 in the ASM-encoding
gene SMPD1 [1, 2]. Insufficient ASM activity results in
the abnormal accumulation of the primary ASM sub-
strate, sphingomyelin, and other metabolically-related
lipids in cells of the monocyte-macrophage system and
other cell types such as hepatocytes. These substrates
can build up over time, causing progressive cell and tis-
sue damage and impairment of the functioning of mul-
tiple organs. The clinical phenotype of ASMD is highly
variable with respect to type and severity of clinical
manifestations and may include functional impairment
of multiple organs. The severity of ASMD-associated
clinical manifestations is influenced by the type of
SMPD1 mutation and appears to reflect the level of re-
sidual ASM activity [4]. Pathologic analyses typically re-
veal large lipid-laden cells, so-called “foam cells”, in the
liver, spleen, lymph nodes, adrenal cortex, lungs and/or
bone marrow [12]. Infants with severe psychomotor de-
generation have profound structural changes in the
brain, associated with neuronal cell loss in cerebral and
cerebellar cortices, gliosis, demyelination and infiltration
of foam cells [12].
Classification of subpopulations
Patients with ASMD have been categorized historically
as NPD A and NPD B based on disease severity and the
presence or absence of neurologic symptoms. Patients
designated as NPD A have a relatively uniform natural
history characterized by severe progressive neurodegen-
eration in the first year of life and death typically by
3 years of age [3, 4]. In contrast, NPD B has a variable
disease course and is associated with a broad spectrum
of disease severity and manifestations. Historically, NPD
B referred to a heterogeneous population of patients
with predominantly chronic progressive visceral mani-
festations of ASMD [5] and no or only minor neurologicsigns and symptoms. Based on evidence presented in the
last decades, it has become increasingly apparent that
many patients with NPD B also may have significant
neurologic symptoms, including progressive neurologic
impairment during childhood [4, 6–8]. To distinguish
patients who have some neurologic manifestations of
ASMD (but do not display the classic NPD A pheno-
type) from those with a classic non-neurologic NPD B
phenotype, they have been variably classified in the lit-
erature as variant NPD B, NPD A/B, intermediate
ASMD or intermediate NPD [4, 6–8]. Thus, ASMD rep-
resents a disease with a continuum of severity that may
not be well defined by the historic NPD A and B classifi-
cation (Table 1). A further source of confusion is the his-
toric grouping of ASMD with NPD type C (NPD C), a
lysosomal storage disorder that is distinct from ASMD
in genetic, pathologic and prognostic aspects, but shares
some clinical features (e.g., spleen enlargement) with
ASMD [9–11]. A more comprehensive system of ASMD
patient stratification based on molecular, clinical and/or
prognostic criteria would be valuable. For the purpose of
this review, NPD B generally refers to all patients not
classified as NPD A, including those with intermediate
phenotypes.
Incidence
Reliable estimates of ASMD incidence worldwide are
currently lacking. Although ASMD is a pan-ethnic gen-
etic disease, many mutations are private and others are
found preferentially in specific ethnic groups [13–20],
which may contribute to differences in disease pheno-
type. The diversity of mutations and frequency of private
mutations make it difficult to conduct widespread gen-
etic carrier screening, which can be further complicated
by the presence of SMPD1 sequence variations that do
not result in loss of ASM function [21].
Another impediment to obtaining precise estimates of
ASMD incidence is the potential for underdiagnosis due
to lack of disease awareness. Although some estimates
based on actual diagnoses place the incidence of ASMD
at approximately 0.5 per 100,000 births [22, 23], esti-
mates extrapolated from the results of carrier screening
suggest that the true incidence may be higher in select
populations. For example, NPD A has a particularly high
prevalence in the Ashkenazi Jewish community, where
three different mutations account for >90% of SMPD1
mutant alleles. Systematic genetic carrier screening for
these three mutations in Ashkenazi Jewish adults sug-
gests a carrier frequency of 1 in 80–100, which would
extrapolate to an estimated two to three cases per
100,000 births in this population [2]. Similarly, estimates
for the Chilean population based on the allele frequency
of a single common SMPD1 mutation associated with
NPD B suggest a rate of approximately two cases per
Table 1 Classification of patients with ASMD based on historical terms
NPD type A Intermediate NPD, variant NPD B NPD type B




Prognosis: death typically by 3 years of age
Phenotype: NPD B phenotype but also progressive neurologic
findings including ataxia, variable degrees of developmental
delay and peripheral neuropathy
Natural history: variable
Prognosis: patients live past early childhood, sometimes into
adulthood
Phenotype: Chronic progressive multi-
system disease with no or little neuro-
logic involvement
Natural history: variable
Prognosis: variable (survival until the
second to seventh decade of life)
ASMD acid sphingomyelinase deficiency, NPD Niemann-Pick disease
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by confirmed diagnoses [24].Diagnosis
Due to the rarity of ASMD and the heterogeneity of its
manifestations, ASMD diagnosis may be missed at initial
presentation or occur only at advanced stages of disease
progression. ASMD should be suspected in patients with
hepatosplenomegaly, developmental delay and/or
cherry-red maculae (also described as “perifoveal white
patch” [25, 26]), interstitial lung disease, hyperlipidemia
characterized by low high-density lipoprotein (HDL)
cholesterol and/or thrombocytopenia. In general, the
diagnosis of ASMD cannot be based solely on clinical
presentation but has to be confirmed by biochemical
and/or molecular genetic testing to distinguish ASMD
from diseases with similar manifestations, such as
Gaucher disease. ASM enzymatic activity can be reliably
measured in peripheral blood lymphocytes or cultured
skin fibroblasts [12]. The diagnosis of ASMD also can be
established by detection of pathogenic SMPD1 variants
through genetic testing. For patients from populations
with common known SMPD1 mutations (e.g., individ-
uals of Ashkenazi Jewish background), targeted analysis
for defined pathogenic mutations can be performed,
with full-length sequence analysis of SMPD1 only re-
quired if the presence of a mutation in both alleles is not
confirmed by other means. In populations in which
common mutations do not exist, full-length sequence
analysis should always be performed.
Newborn screening for ASMD is feasible by testing
the enzymatic activity in dried blood spots [27, 28], and
genotyping of SMPD1 variants, if necessary, can be ac-
complished with the use of the same dried blood spots.
Enzymatic and molecular analysis in noncultivated
chorionic villi also is feasible and permits rapid and ac-
curate prenatal diagnosis of ASMD [10]. Genetic carrier
screening and prenatal diagnosis of ASMD for couples
known to be at risk are available in the Ashkenazi Jewish
community due to the high prevalence of a limited num-
ber of specific SMPD1 mutations [10, 29].
A detailed discussion of the diagnosis of ASMD is be-
yond the scope of this paper. However, a consensus rec-
ommendation on a diagnostic guideline for ASMD,which also provides an overview of the relevant differen-
tial diagnoses, is available [30].Disease manifestations and natural history
Our current understanding of the natural history and
overall clinical burden of ASMD is based on single case
reports, small case series and a limited number of rela-
tively larger observational studies. A literature search in
PubMed since 2004 identified 18 studies that described
the natural history and/or the clinical manifestations of
patients with ASMD (Table 2 [3–8, 20, 24, 31–40]).
However, these studies were often limited in size, ran-
ging from 10 to 103 patients. Therefore, given the gen-
etic and phenotypic heterogeneity of ASMD, caution has
to be exercised when generalizing specific observations.
Similarly, our current knowledge of the disease progres-
sion and causes of death associated with ASMD is based
on few studies [3–5, 31, 32, 36].Manifestations and natural history of NPD A
NPD A is the most severe form of ASMD. Neurologic
findings dominate the NPD A phenotype, which is fairly
homogeneous in terms of natural history, life expectancy
and causes of death [3, 4]. In one study conducted in the
United States, natural history data were reported for 10
infants with NPD A, all of whom presented with hepa-
tosplenomegaly at 2 – 4 months of age [3]. Neurologic
symptoms were first detected at a median age of
7 months, and by 10 months all infants had develop-
mental arrest followed by rapidly progressing neurode-
generation with deterioration of behavioral, language
and gross and fine motor skills. All patients showed pro-
gressive hypotonia with loss of deep tendon reflexes,
whereas cranial nerve function remained largely intact.
Macular cherry-red spots were detectable in all infants
by 12 months. Two patients had hydrocephalus, and
magnetic resonance imaging performed in three infants
revealed delayed myelination in all three patients, widen-
ing of the anterior horn of the left ventricle in two pa-
tients and an arachnoid cyst in one patient [3].
Histopathologic brain analyses from infants with NPD A
typically show characteristic lesions in the cerebellum
and to a lesser extent in the cerebrum, with swollen,
vacuolated ganglion cells, severe myelin deficiency and
Table 2 Observational studies of ASMD clinical burden since 2004
Reference Study type Patients Objective/Evaluation Main findings
Lidove et al.
2016 [45]
Retrospective NPD B (N = 28 adults) Clinical phenotype,
laboratory tests
High frequency of MGUS
Cassiman et al.
2016 [31]




Overall leading causes of death were
respiratory failure and liver failure
Acuña et al.
2015 [24]




Moderate to severe NPD B with normal
cognitive and psychomotor development
McGovern et al.
2013 [32]




NPD B is a life-threatening disorder with














Retrospective ASMD, N = 27
(8 NPD A, 4 intermediate,
15 NPD B)
Genotype, phenotype Comparatively high incidence of NPD A





ASMD, N = 25
(4 severe [NPD A],
6 intermediate, 15
attenuated [NPD B])
Clinical phenotype In NPD B patients, pulmonary disease is
the most debilitating clinical feature
Thurberg et al.
2012 [34]a
Phase 1 trial (rhASM),
(baseline data)
Adults (18–65 years)
with ASMD, N = 17








N = 17; 8 patients
(16–43 years old)
with NPD B, 9 parents
Psychosocial burden of
disease
Limited physical activity and social isolation
and peer rejection are major stressors,










NPD B patients have multi-system
involvement and clinical variable
phenotypes. Almost all had splenomegaly,
hepatomegaly and interstitial
lung disease. Common symptoms:
bleeding (49%), pulmonary infections
(42%), shortness of breath (42%) and
joint/limb pain (39%); low platelets,
abnormal lipid values and liver function
tests. Delayed growth in adolescence. Mild
decrease in QoL with standard instruments
Guillemot et al.
2007 [37]
Retrospective N = 13, 2–9 years old
1 NPD A, 10 NPD B, 2 other (NPD
C)
Lung disease All patients had signs of interstitial lung
disease, 1 patient died of respiratory failure,
5 required long-term oxygen therapy
Mihaylova et al.
2007 [6]
Prospective Intermediate NPD, N = 20,
7 months to 35 years old
Phenotype/genotype
relationship
Variable neural involvement in patients






NPD A, 10 patients (3–6 months
at study entry)
NPD A natural history All infants had severely impaired cognitive
and motor development, cherry-red spots;
median survival from diagnosis was 21
months; cause of death was respiratory




Prospective NPD B, N = 53 Pulmonary findings Interstitial lung disease was present in
most patients; there was no quantitative








10/64 patients had mild hypotonia or





Retrospective ASMD, N = 25 (5 NPD A, 4 NPD B,
16 intermediate ASMD)
Phenotype Description of an intermediate phenotype
with overt, borderline or subclinical
neurologic symptoms of neuronopathy
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Table 2 Observational studies of ASMD clinical burden since 2004 (Continued)
McGovern et al.
J Pediatr 2004 [39]
Prospective Children with ASMD,
N = 40 (10 NPD A; 30 NPD B)
Lipid abnormalities All children had lipid abnormalities including




Prospective NPD B, N = 45 (3–65 years) Ocular manifestations 15/45 patients had macular stigmata





NPD B, N = 29 (2–64 years at study
entry)
NPD B natural history The natural history of NPD B is characterized
by hepatosplenomegaly with progressive
hypersplenism, worsening atherogenic lipid
profile, gradual deterioration in pulmonary
function and stable liver dysfunction
ASMD acid sphingomyelinase deficiency, CHQ-PF50 Child Health Questionnaire – Parental Form 50 for pediatric patients, HDL high-density lipoprotein, LDL low-
density lipoprotein, MGUS monoclonal gammopathy of unknown significance, NPD Niemann-Pick disease, Qol quality of life, rhASM recombinant human ASM,
SF-36 Short-Form 36, TG triglycerides
aReports baseline observational data from a phase 1 clinical trial
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the brain and perivascular connective tissue [12].
A typical clinical feature observed in the 10 infants
with NPD A described above was irritability beginning
around the age of 12 months, with severe sleep disturb-
ance often accompanied by hours-long periods of crying
[3]. These symptoms are likely related to the underlying
neurologic dysfunction. Failure to thrive was com-
pounded by insufficient intake of calories due to worsen-
ing hypotonia, weakened suck and often severe
gastrointestinal symptoms. All infants developed pro-
gressive respiratory symptoms with frequent respiratory
infections secondary to aspiration, and nine of 10 infants
eventually died of respiratory failure. The infants also
had abnormal laboratory values, including elevated liver
enzymes, low HDL cholesterol and progressive decrease
in hemoglobin values and platelet counts; one patient
died of complications from bleeding. The median time
from diagnosis to death was 21 months, with all patients
succumbing at or before the age of 3 years [3]. A recent
study of the disease spectrum and natural history in 25
patients with ASMD in the Netherlands and Belgium in-
cluded four infants with NPD A [4]. Similar to the find-
ings in the US cohort, these patients were all diagnosed
in the first year of life and had early onset of rapidly pro-
gressing deterioration of psychomotor function [4].
Manifestations and natural history of NPD B
Overview
Unlike the fairly homogeneous NPD A phenotype, pa-
tients with NPD B have extensive phenotypic heterogen-
eity, including a wide range of disease manifestations and
severity levels and variable rates of disease progression [5].
A prospective, cross-sectional survey of 59 patients (7–65
years of age) from the United States (n = 26), Brazil (n =
13), Italy (n = 8), France (n = 7) and Germany (n = 5) pro-
vided valuable insight in the spectrum of NPD B disease
manifestations [36]. For each patient, medical history,
physical examinations, assessments of cardiorespiratory
function, clinical laboratory data, liver and spleenvolumes, radiographic assessments of the lungs and bone
age and quality-of-life assessments were obtained accord-
ing to a standardized protocol. The most common symp-
toms at initial presentation among these patients were
splenomegaly (78%) and hepatomegaly (73%), whereas the
most common historical complaints were bleeding (49%,
including recurrent epistaxis in 29%), shortness of breath
(42%), pulmonary infections (42%), joint and/or limb pain
(39%), bruising (27%), headaches (24%), diarrhea (20%)
and bone fractures (19%). Clinical laboratory studies re-
vealed that patients commonly had thrombocytopenia,
low HDL cholesterol and elevated levels of low-density
lipoprotein (LDL) cholesterol, very low-density lipoprotein
cholesterol and triglycerides. Elevated serum chitotriosi-
dase and abnormal liver function tests also were noted.
Several patients had cardiac disease, including one patient
with coronary artery disease who required triple bypass
surgery twice within 10 years. Of interest, the degree of
splenomegaly correlated with hepatomegaly, growth, lipid
profile and hematologic parameters in this study. How-
ever, spleen volume showed only weak negative correla-
tions with measures of pulmonary function, including
percentage of predicted diffusing capacity of the lung for
carbon monoxide (DLCO; r = −0.306, p = 0.052) and per-
centage of predicted forced vital capacity (r = −0.346, p =
0.015), and did not correlate with exercise tolerance as
measured by the 6-min walk test distance (r = −0.260, p =
0.075) [36].
Similar clinical findings were documented in a Dutch
and Belgian study of 25 patients with ASMD [4]. Of the
21 non-NPD A patients, all but one splenectomized pa-
tient had splenomegaly and 19 had hepatomegaly. Thir-
teen of 16 patients available for evaluation had
interstitial lung disease with a variable degree of func-
tional impairment based on pulmonary function testing.
In addition, six of 18 patients had slight anemia, 15 of
18 patients had platelet counts <150 × 109/L and most
had low HDL cholesterol. Thus, as expected from the
underlying pathophysiology, ASMD is associated with
multi-organ disease in most patients.
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class are discussed in detail below and summarized in
Fig. 1.
Splenomegaly Splenomegaly is one of the most com-
mon disease manifestations of NPD B [4, 5, 36] and
often the first obvious sign of the disease. Evidence from
histological spleen samples obtained after surgery, sug-
gests that splenomegaly is essentially the result of infil-
tration by lipid-laden macrophages [12]. The spleen size
can be massive and, as discussed above, may be a surro-
gate marker of disease severity because of its correlation
with other disease parameters [36]. In the cross-
sectional study of 59 pediatric and adult patients with
NPD B (7 – 65 years of age), splenic volume ranged
from 3.1 to 27.3 multiples of normal, with 85% of theFig. 1 ASMD manifestations in patients with NPD B, in the currently publis
sphingomyelinase deficiency; AST aspartate amino transferase; BMC bone mpatients having spleen volumes greater than 5 multiples
of normal [36]. Large spleen size was associated with in-
creased incidence of bleeding and bruising; however, al-
though splenomegaly may be associated with secondary
hypersplenism, the study found no significant correlation
between spleen volume and platelet count [36].
Pulmonary disease Most patients in the cross-sectional
study [36] of 59 patients with NPD B (90%) as well as
most patients in a prospective study [38] of 53 patients
with NPD B 7 – 65 years of age (90%) had evidence of
interstitial lung disease by chest radiography and high-
resolution computed tomography. However, the prospect-
ive study [38] did not find a strong correlation between
radiologic findings and the results of pulmonary function
tests. Some patients with markedly abnormal imaginghed literature. ALT alanine amino transferases; ASMD acid
ineral content; BMD bone mineral density; NPD Niemann-Pick disease
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change, and some patients with marked gas exchange im-
pairment (DLCO <60% of predicted value) had only mildly
abnormal imaging findings [38]. Therefore, imaging stud-
ies are not sufficient in the evaluation of pulmonary dis-
ease in NPD B and must be interpreted in conjunction
with functional testing and the clinical status of the pa-
tient. Among patients with functional pulmonary disease,
the most common findings are low forced vital capacity
and DLCO, which are consistent with restrictive lung dis-
ease and impaired gas exchange secondary to interstitial
lung disease. A natural history study of 29 pediatric and
adult patients with NPD B documented slow progression
of pulmonary disease with small mean annual changes in
all measures of pulmonary function [5]. Slow progression
of pulmonary disease also has been reported by others
[37]. Overall, respiratory disease is one of the most com-
mon manifestations and a leading cause of death in pa-
tients with NPD B [31, 32].
Liver disease In a study of morbidity and mortality in
103 patients with NPD B carried out at a single center
between 1992 and 2012, six patients had fulminant liver
failure, and liver biopsies from three additional patients
showed evidence of cirrhosis [32]. Two of the patients
with liver failure received successful orthotopic liver
transplants at 12 and 25 years of age, whereas three of
four patients who did not receive a transplant died from
liver failure [32].
In the cross-sectional study of 59 patients with NPD
B, alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) were elevated in 51% of the patients,
and total bilirubin was elevated in 33% of patients [36].
In the natural history study of 29 patients with NPD B
(2–64 years of age at study entry), liver dysfunction was
common, with 75% of patients having elevated ALT and
65% having elevated AST at the initial visit. However,
overall no statistically significant changes in liver enzyme
values over time were noted [5]. One patient developed
hepatic dysfunction approximately 2 years after his last
visit and subsequently died of liver failure [5]. Another
study, a systematic analysis of liver biopsies from 17
adult patients with NPD B revealed the presence of liver
fibrosis in 15 patients. Two of the patients (39 and
40 years of age) had frank cirrhosis in the absence of any
clinical symptoms of liver failure [34]. A recent case re-
port of a patient who died at the age of 31 years from re-
fractory encephalopathy related to cirrhosis and hepatic
failure, further illustrates that hepatic tests may be nor-
mal despite evidence of extensive cirrhosis in liver biop-
sies [41].
In a series of 13 Chilean pediatric patients homozy-
gous for the SMPD1 p.(Ala359Asp) (A359D) mutation
associated with moderate to severe NPD B, five (38.5%)patients developed clinically relevant liver disease due to
progressive cirrhosis [24]. Notably, all five patients had
sustained approximately four-fold increases in ALT and
AST. Three of these patients succumbed to liver failure
in childhood and the other two received liver transplants
[24]. In summary, available evidence suggests that the
prevalence of liver disease is high and that the incidence
of clinically significant liver disease varies in different pa-
tient populations, and may be as high as 40% in some
NPD B subpopulations. In addition to respiratory dis-
ease, liver failure is the most common cause of death in
patients with NPD B [31].
Skeletal disease According to medical history, 19% of
the patients in the cross-sectional study had suffered
one or more bone fractures [36]. A subsequent detailed
examination of the skeleton was carried out in 20
pediatric and 26 adult patients with NPD B, including
Dual X-ray Absorptiometry scans to measure bone min-
eral content (BMC) and bone mineral density (BMD)
[33]. Five (25%) pediatric and 14 (53%) adult patients
had a history of skeletal fracture. Additionally, 12 (60%)
pediatric patients had experienced back and leg pain and
15 (58%) adult patients had experienced back pain.
Pediatric patients had significant decreases in adjusted
mean BMC and BMD at the lumbar spine, hip and fem-
oral neck compared with a cohort of healthy age-
matched subjects. In addition, most adults with NPD B
had osteopenia or osteoporosis at one or more sites ac-
cording to the World Health Organization classification
of BMD [33]. These findings demonstrate that skeletal
involvement is a common feature of ASMD.
Cardiac disease and hyperlipidemia In the cross-
sectional study, electrocardiogram abnormalities were
present in 16 of 58 (28%) patients evaluated [36]. These
included sinus bradycardia (n = 6), left ventricular hyper-
trophy (n = 4) and conduction abnormalities (n = 6).
Two-dimensional echocardiograms showed abnormal-
ities in 29 (50%) patients, most commonly mild mitral
valve regurgitation. However, two patients had previ-
ously undiagnosed moderate to severe aortic regurgita-
tion and one patient had pulmonary hypertension [36].
Most patients in the cross-sectional study [36] had an
atherogenic lipid profile characterized by low HDL chol-
esterol (74% of 58 patients; mean 26 mg/dL), high total
cholesterol (41% of 58 patients), high triglycerides (62%
of 58 patients) and high LDL (46% of 57 patients) and
very low-density lipoprotein (62% of 34 patients) choles-
terol compared with age- and gender-matched control
subjects. The mean total cholesterol/HDL cholesterol ra-
tio (n = 58) of 10.3 was 2.3 times the upper limit of nor-
mal [36]. In a study of pediatric patients with ASMD,
including 10 with NPD A and 30 with NPD B, all
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Mean levels of total, HDL and LDL cholesterol, and tri-
glycerides were abnormal in both NPD A and NPD B
patients, with no substantial differences between the two
groups. Furthermore, electron beam tomography of the
coronary arteries performed in 18 NPD B patients re-
vealed positive calcium scores (range 1.4–34.5) in 10 pa-
tients, which in patients <18 years of age suggests the
presence of early atherosclerosis. Age and coronary ar-
tery calcium scores in this pediatric population were
strongly correlated (r = 0.79, p < 0.0001), and the highest
score (34.5; >95th percentile for age and sex) was
present in a 18 year old female [39]. Thus, cardiac and
cardiovascular involvement is part of the ASMD pheno-
type at an early age. Consistent with these findings, a
systematic evaluation of morbidity and mortality in 103
patients with NPD B further showed that 9% of the pa-
tients had coronary artery or heart valve disease [32].Hematologic findings The cross-sectional study docu-
mented bleeding episodes in 49% of the 59 patients en-
rolled [36]. The most common bleeding event was
recurrent epistaxis in 29% of patients, with two patients
requiring repeated cauterizations. Significant bleeding
events in one patient each included subdural hematoma,
hematemesis, hemoptysis, hemothorax, excessive bleed-
ing after tonsillectomy and adenoidectomy resulting in a
blood transfusion, menorrhagia and uterine bleeding
that required a hysterectomy [36]. Recurrent epistaxis
also was a clinical characteristic of all 13 Chilean pa-
tients with homozygous SMPD1 A359D mutations in a
recent study [24]. Presumably, these bleeding episodes
are related in part to thrombocytopenia, which in the
cross-sectional study was present in 53% of patients at
the time of evaluation and the most common
hematologic abnormality. In comparison, anemia and
leukopenia were present in 26% and 21% of patients, re-
spectively [36].Growth Growth data collected in the cross-sectional
study [36] revealed that most patients with NPD B had
below average height and weight, with mean z scores
(based on normative growth data from the Centers for
Disease Control) of −1.3 (range −4.88 – 2.14) and −0.77
(range −5.22 – 1.80), respectively. Growth delay was
most pronounced in adolescents (mean height z score
−2.60, in patients 13–17 years of age), who also had de-
layed bone age that corresponded with delayed puberty.
However, most adults (≥18 years of age) had heights in
the low normal range (mean height z score −0.58), sug-
gesting that a period of catch-up growth occurs in late
adolescence and/or early adulthood [36]. Thus, although
short stature is a cause of concern for adolescentpatients with NPD B, final adult heights appear to ap-
proach normal values in most patients.
Neurologic manifestations of variant NPD B
As noted above, there are patients with ASMD who do
not present with the classic NPD A phenotype but have
variable neurologic symptoms ranging from mild hypo-
tonia or hyporeflexia to severe progressive neurologic
abnormalities such as loss of motor function and mental
deterioration [4, 6–8, 32, 42, 43]. In these patients, the
onset of neurologic symptoms is later in life than in pa-
tients with NPD A and are not characterized by rapid
progression. In a report of 25 Czech and Slovak patients
with ASMD who did not demonstrate the classic NPD A
phenotype, 16 (64%) displayed a spectrum of neurologic
symptoms [7]. In this case series, 12 of the 16 patients
had the Q292K mutation in homoallelic or heteroallelic
form, and 10 of those had a protracted neurovisceral
phenotype [7]. In a prospective US study of 64 patients
with NPD B who underwent detailed neurologic and
ophthalmologic examinations, 19 (30%) were found to
have neurologic abnormalities, again suggesting that pa-
tients with a phenotype that includes neurologic mani-
festations constitute a significant proportion of ASMD
patients in addition to the NPD A patient population
[8]. The most common abnormalities were mild hypo-
tonia and/or hyporeflexia, which were found in 10 pa-
tients. Five of the 19 patients, who had been diagnosed
between the ages of 15 months and 5 years, had progres-
sive neurologic abnormalities. Unlike infants with NPD
A, these five patients reached their normal developmen-
tal milestones at least during the first 2 years of life.
Varying from patient to patient, the onset of neurologic
difficulties, which included cognitive impairment (men-
tal deterioration or expressive language delay) and/or
other moderate to severe neurologic symptoms, oc-
curred at 2 – 7 years of age [8]. Patients with macular
cherry-red spots often but not always had neurologic ab-
normalities [8, 40].
Of note, a patient with NPD B who was diagnosed at
age 59 and died at age 60 from severe restrictive lung
disease, also had Parkinson’s disease [4]. Although the
pathogenic relationship between ASMD and Parkinson’s
disease in this patient is unknown, it recently has been
suggested that at least some SMPD1 mutations are asso-
ciated with an increased risk of Parkinson’s disease [44].
A recent paper analyzing the phenotype of 28 adult
French patients with ASMD found a peripheral neur-
opathy (n = 3), depression requiring anti-depressant ther-
apies (n = 3), and psychosis (n = 1) [45].
Natural history of NPD B
In a single-center longitudinal US study, 29 patients with
NPD B had serial evaluations over a 10-years period to
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spleens had splenomegaly, with spleen volumes ranging
from 4.5 to 27.3 multiples of normal. In addition, all but
one patient had hepatomegaly. Progressive decreases in
platelet and leukocyte count over time were docu-
mented, as was an overall worsening of the atherogenic
lipid profiles. Similarly, all measurements of pulmonary
function showed a gradual but slow deterioration over
time, whereas liver dysfunction was generally character-
ized by stable elevation of liver enzymes and bilirubin
[5]. The natural disease course of NPD-B patients was
evaluated in a recent study among patients from the
Netherlands and Belgium [4]. Of the twenty-one non-
NPD A patients, only six patients with the attenuated
form of NPD-B were included in the prospective natural
history study; four patients had a detailed follow-up up
through to 6 years. A detailed assessment of these pa-
tients revealed stable disease parameters, with slow pro-
gression of pulmonary disease [4]. In the study of 13
pediatric Chilean patients with homozygous SMPD1
A359D mutations, five developed fulminant liver failure
over an average follow-up period of 10 years [24]. The
different observations in these study populations reflect
the heterogeneity of natural history in patients with
NPD B and may be related to the underlying SMPD1 ge-
notypes. In both the US [5] and European [4] studies, a
variety of SMPD1 mutations were present, whereas the
study with Chilean patients [24] included the same
genotype.
Mortality
As noted above, mortality in NPD A is most frequently
due to respiratory failure by the age of 3 years [3]. In
contrast, mortality data for NPD B are too heteroge-
neous and limited to allow for the construction of sur-
vival curves. Available evidence suggests that survival
among patients with NPD B varies significantly, consist-
ent with their phenotypic heterogeneity. Although many
patients do not survive into adulthood, some have
reached their fifth or sixth decade of life [32]. Results of
an analysis of morbidity and mortality in 103 patients
with NPD B that also included patients with significant
neurologic manifestations were recently reported [32]. A
total of 18 patients died during the 20-years study
period, at a median age of 15.5 years (range 1–72 years).
Twelve deaths occurred in patients aged ≤21 years,
yielding a mortality rate of 19% in this age group. Over-
all, the most common causes of death were pneumonia/
respiratory failure (five patients), acute liver failure
(three patients), bleeding complications (three patients)
and complications from bone marrow transplants (three
patients); other causes of death (each in one patient) in-
cluded multi-organ failure, heart failure and liver cancer
[32].A more recent study evaluated disease-related morbid-
ities and the primary causes of death in 85 patients: with
chronic visceral ASMD (NPD B excluding variant NPD
B, n = 58) and chronic neurovisceral ASMD (variant
NPD B, n = 27), including 78 patients who had died and
seven patients who had received liver transplants be-
cause of terminal liver disease [31]. Overall, the most
common causes of death were respiratory disease (27.7%
of patients) and liver disease (27.7%), followed by bleed-
ing (9.6%) and cardiac disease (7.2%). The median age at
the time of death was 23.5 and 8 years for patients with
chronic visceral and chronic neurovisceral ASMD, re-
spectively. Among patients with chronic neurovisceral
ASMD (31.8%), neurodegenerative disease progression
was a leading cause of death (23.1%), along with respira-
tory disease (23.1%) and liver disease (19.2%) [31].
Genotype-phenotype relationship
More than 180 different SMPD1 mutations have been
identified to date in patients with ASMD, including mis-
sense, nonsense, frameshift mutations and splice variants
[46]. Because of the recessive nature of these mutations,
ASMD generally requires the inheritance of two mutant
alleles. However, SMPD1 is a preferentially paternally
imprinted gene [47]. Consequently, heterozygous car-
riers of a maternal SMPD1 mutation may show mild
forms of ASMD [47]. Predicting ASMD natural history
based on genetic data is challenging because of the
multitude of possible allelic combinations and because
many mutations are private [15]. Nevertheless, extensive
mutational analyses in ASMD patient communities
worldwide have provided some insight into important
genotype-phenotype relationships [13, 20]. For example,
NPD A in the Ashkenazi Jewish community is predom-
inantly associated with three SMPD1 mutations (R496L,
L302P and fsP330) [48–50]. Because of the obvious
prognostic and diagnostic significance of these muta-
tions, carrier screening is an important tool for genetic
counseling in this community. In Chile, a single SMPD1
mutation (A359D) may account for most cases of NPD
B and appears to be associated with a typical clinical
phenotype with normal cognitive and psychomotor de-
velopment but moderate to severe visceral disease mani-
festations, including a high incidence of clinically
significant liver disease [24]. The R610del mutation is
the most common mutation in patients with ASMD,
with a particularly high prevalence among patients of
North African origin [51]. It is associated with an atten-
uated NPD B phenotype and considered “neuroprotec-
tive”, as even pairing with a null allele or another
deleterious neuronopathic allele (e.g., R496L) did not
lead to progressive neurodegenerative disease [8, 13].
However, some patients heterozygous for the R610del al-
lele have mild hypotonia or hyporeflexia [8]. 677delT
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NPD A in Israeli Arabs and with NPD B in northern Af-
rica, respectively [51, 52].
Evidence from two studies suggests that the Q292K
mutation is strongly associated with neurologic involve-
ment. Specifically, the Q292K mutation was present in
heteroallelic or homoallelic form in 10 of 12 Czech and
Slovak patients with progressive neurologic disease [7],
and three of four patients with a Q292K mutation
(homoallelic or paired with a null allele) had progressive
neurologic symptoms in a US study [8]. In contrast, in a
group of 20 patients with an intermediate phenotype
who were homozygous for a unique ancestral SMPD1
mutation (W391G), neurologic manifestations were gen-
erally highly diverse but similar among relatives [6]. This
raises the possibility that, in addition to the SMPD1 mu-
tation profile, other genetic factors may influence the
ASMD phenotype.
Quality of life, psychosocial and economic burden
Information about the impact of ASMD on health-
related quality of life (QoL) and the psychosocial burden
of ASMD has to be derived from case reports, as very
few studies have attempted to address these topics.
Owing to the rarity and heterogeneity of ASMD, there is
a lack of robust quantitative data regarding the impact
of the disease on patients’ and caregivers’ QoL. This de-
ficiency is compounded by the lack of validated disease-
specific instruments to evaluate QoL in patients with
ASMD, and the limitations of generic QoL instruments
in providing useful quantitative data [36]. The economic
impact of ASMD on the affected individuals and their
families has not been studied.
The devastating burden of NPD A for the affected chil-
dren and their families in terms of physical and emotional
impact is self-evident and reflected in testimonials by par-
ents of children with the disease [53]. Before or by the age
of 1 year, infants with NPD A show increased signs of ir-
ritability and discomfort, including inability to sleep, pro-
longed periods of crying and frequent vomiting [3].
Around-the-clock care for their infants has a profound
negative effect on caregivers’ QoL. In addition, physical
and occupational therapy for children with NPD A as well
as frequent hospitalization resulting from respiratory in-
fections can be expected to be associated with a significant
economic burden for the patients’ families [3].
A single study [36] assessed QoL in a limited number
of adult and pediatric patients with NPD B using generic
QoL instruments (i.e., the Child Health Questionnaire –
Parental Form 50 for pediatric patients [CHQ-PF50] and
the Short-Form 36 [SF-36] for adults). Four of 10
pediatric patients had CHQ-PF50 subscale scores sug-
gesting diminished QoL associated with physical func-
tioning, mental health, general health perceptions and/oremotional well-being. Using the SF-36, the study found
only mild decreases in the score in adult patients com-
pared with the US general population [36]. The apparent
inconsistency of these QoL findings with the known
clinical symptom burden of the patients (see above) [36]
illustrates the need for validated age-adequate ASMD-
specific QoL instruments.
The human experience and psychosocial impact of the
disease has been evaluated in a small number of adoles-
cent and adult patients with NPD B (n = 8) and the par-
ents (n = 9) of the adolescent patients [35]. The study
identified psychosocial problems based on interviews
with patients and caregivers, and six patients (three
adults and three adolescents) provided quantitative data
for a measure of psychosocial development. Limited
physical activity and social isolation were identified as
major psychosocial stressors in all patients. In pediatric
patients, social isolation was often linked to exclusion
from physical activities such as roughhousing, soccer
and wrestling, which increase the risk for splenic rupture
and are discouraged. In addition, juvenile patients often
suffered from peer rejection owing to enlarged abdomen
from hepatosplenomegaly, growth and developmental
delay. For adults, chronic fatigue and lack of energy ap-
peared to be major factors leading to social isolation
[35]. In the quantitative test of psychosocial develop-
ment, participants’ scores indicated resolution conflicts
related to intimacy, isolation, ego integrity and despair,
consistent with anxiety and feelings of missed opportun-
ities in life, particularly in the area of relationships. Pa-
tients and parents also consistently expressed frustration
about the lack of treatment and paucity of medical infor-
mation [35].
Parents and caregivers often have difficulties maintain-
ing their emotional and mental health while caring for
their children with a life-threatening disease. In addition,
afflicted families may face extreme financial burden
given that the multifaceted disease course in many
pediatric and adult patients is associated with repeated
emergency hospitalization, particularly for bleeding
events and respiratory complications, chronic need for
supportive care such as oxygen therapy or psychosocial
care, and progressive mental or physical disability that
may require expensive special therapies [32].
Overall, there is a lack of quantitative and qualitative
data on QoL and the impact of the disease on patients
and families. In addition, there is limited information as
to the specific disease manifestations that are most
bothersome to patients with ASMD and how they affect
their daily functioning and QoL.
Therapeutic options
There are currently no curative therapies for ASMD.
Some experimental approaches including bone marrow
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transplant have been attempted but do not have a favor-
able benefit/risk ratio owing to their uncertain impact
on short- and long-term disease outcomes and consider-
able risk of complications [2]. Splenectomy may be re-
quired in cases of extensive spleen necrosis with loss of
function [54] or rupture [55, 56]; however, it is generally
not recommended as it may exacerbate pulmonary dis-
ease [36]. Thus, management of patients with ASMD is
limited to supportive care and palliation, which requires
a multidisciplinary approach [9]. Physical and occupa-
tional therapy in infants with NPD A may be beneficial
but should be directed with realistic goals. Patients with
progressive pulmonary disease may require chronic oxy-
gen therapy and modification of their daily activities.
Vaccination against influenza and Streptococcus pneumo-
niae species should be considered to minimize the risk
of pneumonia. Standard lipid-lowering agents are indi-
cated for the treatment of ASMD-associated lipid abnor-
malities in adult patients. Although some patients have
undergone growth hormone treatment for short stature
with consequent acceleration of linear growth [57], most
patients have a period of catch-up growth with contin-
ued acquisition of height into their twenties. To date, no
treatment approach has been reported to positively
affect low bone density, and there are no effective treat-
ments to reduce hepatosplenomegaly. Because of low
platelet count and risk of hematoma or bleeding, sports
involving strong physical contact, such as soccer and
wrestling, must be avoided. Many patients rarely become
anemic enough to require transfusions. However, pa-
tients with clinically significant cytopenia and a history
of excessive bleeding may require multiple blood
transfusions.
Enzyme replacement therapy (ERT) with recombinant
human ASM is a potentially disease-modifying thera-
peutic approach currently in clinical development for
the treatment of ASMD. ERT represents a known mech-
anism of action that has been used successfully in other
lysosomal storage disorders [58]. Results of a 26-weeks
phase 1b study in five adult patients with NPD B estab-
lished initial proof of concept for the safety and efficacy
of recombinant human ASM in this patient group, in-
cluding reductions in sphingomyelin storage seen in liver
biopsies, spleen and liver volumes and serum chitotriosi-
dase activity, and improvements in infiltrative lung dis-
ease, lipid profiles, platelet counts and QoL assessments
[59]. A phase 1/2 clinical trial in pediatric patients and a
phase 2/3 trial in adult patients with ASMD are ongoing
[60–62].
Conclusions
ASMD is a rare genetic, progressive life-threatening dis-
ease with highly variable severity and disease course.NPD A has a devastating clinical course associated with
onset of rapidly progressing psychomotor degeneration
often shortly after the first 6 months of age. Children
typically die from respiratory failure by the age of 3 years.
NPD B is a chronic progressive disease, representing a
spectrum of phenotypes with varying severity levels, pro-
gression rate and prognosis. NPD B is associated with a
substantial burden for many patients, caused by the pro-
foundly negative impact of its clinical manifestations on
physical, mental and psychosocial well-being. However,
published data regarding the impact of the disease on
QoL and daily functioning are limited, mainly owing to
the rarity and heterogeneity of the disease and the lack
of adequate disease-specific instruments to measure
QoL. Given the wide spectrum of NPD B phenotypes,
including intermediate forms characterized by mild to
severe neurologic defects in addition to visceral, skeletal
and hematologic ASMD manifestations, a refinement of
the ASMD classification system is needed. A more pre-
cise description of ASMD subpopulations may improve
disease recognition at initial presentation and thus lead
to more timely diagnoses. Better characterization and
delineation of different ASMD subpopulation will re-
quire additional studies able to improve our current un-
derstanding of the disease and the factors that influence
disease phenotype, natural history and prognosis.
Endnotes
1There are currently two numbering systems for
SMPD1 mutations as a result of two reference sequences
(GenBank Accession Numbers NM_000543.4 and
M81780.1) that differ by a length polymorphism within
the signal peptide region. Reference to mutations should
refer to the appropriate reference sequence for clarity; in
this paper, the NM_000543.4 sequence was used.
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